Company BAR1 LIFE Australian S.E.

Equities

BD1

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-.--%

Apr. 19	INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test	MT
Apr. 15	Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares	MT

INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.

AUD in Million	2022	Weight	2023	Weight	Delta
Human Telomerase Reverse Transcriptase 91.2 %	0	99.0 %	0	91.2 %	+32.61%
Molecular Nets 8.8 %	0	1.0 %	0	8.8 %	+1,128.37%

AUD in Million	2022	Weight	2023	Weight	Delta
South Korea 60.4 %	0	1.0 %	0	60.4 %	+8,350.67%
United States 39.6 %	0	99.0 %	0	39.6 %	-42.49%

Managers	Title	Age	Since
Leearne Hinch CEO	Chief Executive Officer	-	16-11-06
Mark Edwards DFI	Director of Finance/CFO	-	22-11-01
Gregory Rice CTO	Chief Tech/Sci/R&D Officer	-	21-09-19

Members of the board	Title	Age	Since
David John Williams CHM	Chairman	70	Nov. 28
Philip Powell BRD	Director/Board Member	65	19-06-17
Geoff Cumming BRD	Director/Board Member	-	20-07-27
Robert Johnston BRD	Director/Board Member	-	19-06-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	92,018,702	65,958,065 ( 71.68 %)	0	71.68 %

Name	Equities	%	Valuation
Merchant Funds Management Pty Ltd. 14.22 %	13,082,057	14.22 %	5 M $
David John Williams 5.311 %	4,886,671	5.311 %	2 M $
Irmgard Irminger-Finger 4.163 %	3,830,756	4.163 %	2 M $
Lesamourai Pty Ltd. 1.701 %	1,565,000	1.701 %	622 807 $
Traoj Pty Ltd. 1.199 %	1,102,933	1.199 %	438 923 $
Supergun Pty Ltd. 1.108 %	1,020,000	1.108 %	405 919 $
Nathan Ryan Wagner 1.098 %	1,010,433	1.098 %	402 112 $
David Neate 0.9805 %	902,257	0.9805 %	359 062 $
Peter Cook 0.9781 %	900,000	0.9781 %	358 164 $
Trovex Pty Ltd. 0.8911 %	820,000	0.8911 %	326 327 $

INOVIQ Ltd.

23 Normanby Road

3168, Notting Hill

+61 3 9548 7586

http://www.inoviq.com

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.32%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research